CpG Oligonucleotide Immunotherapy for Activating Cold Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy methods, including the use of checkpoint inhibitors, have limited efficacy due to the inhibition of anti-tumor immune responses by negative mediators such as IL-10 and PD-1, and are often ineffective in tumors lacking pre-existing immunity, necessitating improved strategies to enhance immune activation and reduce inhibition.
Innovation Solution
The use of specific subtypes of CpG oligonucleotides with reduced phosphorothioate modifications, administered intratumorally or peritumorally, in combination with checkpoint inhibitors and radiotherapy, to induce high levels of type I IFN and promote CD8+ T-cell infiltration, converting 'cold' tumors to 'hot' ones amenable to treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If checkpoint inhibitors are used to treat cancer, then immune activation is enhanced, but efficacy is limited by negative mediators such as IL-10 and PD-1
Solution Approach 1:
The patent converts the harmful immune-suppressive effects of IL-10 and PD-1 into beneficial outcomes by using them as targets for inhibition. Specifically, the composition includes agents that block IL-10 signaling and PD-1/PD-L1 interactions, thereby transforming the previously harmful immune suppression into enhanced anti-tumor immune responses. This approach directly addresses the limitation of checkpoint inhibitors by adding complementary mechanisms to overcome immune suppression.
Solution Approach 2:
The patent employs a composite therapeutic approach by combining multiple agents in a single composition: checkpoint inhibitors, IL-10 inhibitors, and other immune-modulating compounds. This multi-component composition works synergistically to enhance immune activation while simultaneously blocking multiple pathways of immune suppression, thereby improving overall treatment efficacy beyond what single agents can achieve.
2Ease of operation
If checkpoint inhibitors are used alone, then treatment is simplified, but efficacy is limited in tumors lacking pre-existing immunity
Solution Approach 1:
The patent merges multiple therapeutic mechanisms into a single unified composition that can be administered together. The composition combines checkpoint inhibitors with IL-10 inhibitors and other immune-modulating agents, creating a synergistic formulation that addresses both hot and cold tumors. This merging approach maintains operational simplicity (single administration) while dramatically improving efficacy across different tumor types by providing multiple simultaneous immune-enhancing mechanisms.
3Reliability
If multiple agents are combined to overcome immune suppression, then treatment efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent resolves the complexity issue by merging multiple therapeutic agents into a single pre-formulated composition that can be administered as one treatment. This unified approach maintains the benefits of multi-agent therapy (enhanced efficacy through synergistic mechanisms) while eliminating the operational complexity of administering multiple separate agents at different times and routes.
4Reliability
If high levels of immune activation are induced, then anti-tumor response is enhanced, but immune suppression by negative mediators increases
Solution Approach 1:
The patent applies preliminary anti-action by including IL-10 inhibitors and PD-1/PD-L1 blockers in the composition before immune activation is induced. This preemptive approach blocks the pathways that would otherwise lead to immune suppression, allowing high levels of immune activation to proceed without being counteracted by suppressive mediators. The inhibitory agents are already in place to prevent the harmful feedback loop that normally limits immune responses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances tumor immunotherapy by inducing a Th1-like microenvironment, increasing T-cell infiltration, and improving treatment efficacy in tumors resistant to single-agent therapies, including those with limited pre-existing immunity.
Implementation Method 1
The use of specific subtypes of CpG oligonucleotides with reduced phosphorothioate modifications, administered intratumorally or peritumorally, in combination with checkpoint inhibitors and radiotherapy, to induce high levels of type I IFN and promote CD8+ T-cell infiltration
Implementation Method 2
The use of specific subtypes of CpG oligonucleotides with reduced phosphorothioate modifications, administered intratumorally or peritumorally, in combination with checkpoint inhibitors and radiotherapy
Data Source
AI summary
Provided are compositions and methods for treating cancer using administration of certain volumes of CpG oligonucleotides (CpG ODN) and, optionally, administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.